Back to News
Market Impact: 0.1
Candel Therapeutics Adds Regulatory Executive Martine Zimmermann To Board As BLA Filing Nears
Source: Nasdaq
Healthcare & BiotechManagement & Governance
Candel Therapeutics appointed Martine Zimmermann, PharmD, to its board of directors effective September 8, 2026. The clinical-stage immunotherapy company's announcement is a routine governance update with limited expected near-term valuation impact.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.10
Ticker Sentiment
CADL0.20
More News
- Apollo in talks to buy J&J orthopedics unit for nearly $20 billion
- Apollo Global in talks to acquire J&J’s orthopedics unit, Bloomberg News reports
- Flavio Bolsonaro faces corruption probe weeks before Brazil election
- Federal budget deficit reaches $2T in first 11 months of fiscal year 2026, CBO reports
- Super Micro Computer Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Super Micro Computer, Inc.
- Scholar Rock Announces FDA Approval of ISEMBYLD™ (apitegromab-mstn), the First and Only Muscle-Targeted Treatment for Children and Adults with Spinal Muscular Atrophy (SMA)